Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNASDAQ:ANLNASDAQ:INCRNASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$0.85+5.8%$0.95$0.61▼$16.50$12.76M-0.151.12 million shs259,351 shsANLAdlai Nortye$1.65-4.9%$1.89$1.10▼$4.32$60.89M-0.8312,330 shs26,519 shsINCRInterCure$1.50+2.0%$1.47$1.17▼$2.62$68.36M1.2227,346 shs1,546 shsMCRBSeres Therapeutics$8.23+13.4%$8.87$6.53▼$30.60$63.40M2.62139,987 shs120,268 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%+0.13%-20.93%-20.18%-95.03%ANLAdlai Nortye0.00%-11.29%-10.33%-30.08%-68.28%INCRInterCure0.00%-5.66%-6.25%-7.98%-41.18%MCRBSeres Therapeutics0.00%+13.99%+17.99%-46.24%-63.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.6916 of 5 stars0.04.00.00.02.20.00.6ANLAdlai Nortye1.2413 of 5 stars3.33.00.00.01.00.00.0INCRInterCure0.3805 of 5 stars0.03.00.00.01.80.00.6MCRBSeres Therapeutics2.9477 of 5 stars2.91.00.04.62.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/AANLAdlai Nortye 2.50Moderate Buy$9.00445.45% UpsideINCRInterCure 0.00N/AN/AN/AMCRBSeres Therapeutics 1.75Reduce$73.67795.10% UpsideCurrent Analyst Ratings BreakdownLatest ALLR, INCR, ANL, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.003/20/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/14/2025MCRBSeres TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $15.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A($559.39) per shareN/AANLAdlai Nortye$5M12.18N/AN/AN/A∞INCRInterCure$238.85M0.29N/AN/A$2.72 per share0.55MCRBSeres Therapeutics$126.33M0.57N/AN/A($0.35) per share-23.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%8/4/2025 (Estimated)ANLAdlai Nortye-$104.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)INCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/AN/AMCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%8/12/2025 (Estimated)Latest ALLR, INCR, ANL, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.752.75ANLAdlai NortyeN/A1.85N/AINCRInterCure0.151.781.15MCRBSeres TherapeuticsN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%ANLAdlai Nortye35.21%INCRInterCure8.34%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%ANLAdlai NortyeN/AINCRInterCure0.24%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million4.43 millionNot OptionableANLAdlai Nortye12736.90 millionN/ANot OptionableINCRInterCure35045.57 million45.46 millionOptionableMCRBSeres Therapeutics3308.73 million162.03 millionOptionableALLR, INCR, ANL, and MCRB HeadlinesRecent News About These CompaniesSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average - Here's What HappenedJune 5 at 5:11 AM | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest UpdateJune 3, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives $73.67 Average Price Target from AnalystsMay 31, 2025 | americanbankingnews.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Reduce" by BrokeragesMay 29, 2025 | marketbeat.comSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?May 23, 2025 | zacks.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average - Here's WhyMay 19, 2025 | marketbeat.comWall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to TradeMay 16, 2025 | zacks.comStockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to HoldMay 11, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.comMay 11, 2025 | marketbeat.comSeres Therapeutics' (MCRB) Neutral Rating Reaffirmed at Chardan CapitalMay 10, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6, 2025 | msn.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%May 6, 2025 | aaii.comSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative Gains3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidBy Chris Markoch | May 19, 2025View 3 Companies That Just Raised Dividends; 2 to Buy, 1 to Avoid3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest LoserBy Leo Miller | May 13, 2025View 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest LoserLockheed Martin: A Top Defense Pick in 2025By Jeffrey Neal Johnson | May 16, 2025View Lockheed Martin: A Top Defense Pick in 2025AMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted GearsALLR, INCR, ANL, and MCRB Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$0.85 +0.05 (+5.84%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.29%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Adlai Nortye NASDAQ:ANL$1.65 -0.09 (-4.90%) Closing price 06/6/2025 03:58 PM EasternExtended Trading$1.66 +0.01 (+0.30%) As of 06/6/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.InterCure NASDAQ:INCR$1.50 +0.03 (+2.04%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.47 -0.03 (-2.00%) As of 06/6/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Seres Therapeutics NASDAQ:MCRB$8.23 +0.97 (+13.36%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$8.20 -0.03 (-0.30%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
